EMA Authorised: Empliciti (Elotuzumab) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

EU authorities have authorised Empliciti (elotuzumab) for multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Empliciti (elotuzumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 25/09/2025. Accelerated assessment